Published in final edited form as:

Bioorg Med Chem. 2008 January 15; 16(2): 822–829.

A New Synthesis of the ORL-1 Antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidiny]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397) and Activity in a Calcium Mobilization Assay

Emilie D. Smith¹, N. Ariane Vinson¹, Desong Zhong¹, Bertold D. Berrang¹, Jennifer L. Catanzaro¹, James B. Thomas¹, Hernán A. Navarro¹, Brian P. Gilmour¹, Jeffrey Deschamps², and F. Ivy Carroll^{1*}

¹Organic and Medicinal Chemistry, Research Triangle Institute, P. O. Box 12194, Research Triangle Park, NC 27709

²Laboratory for the Structure of Matter, Naval Research Laboratory, 4555 Overlook Avenue, Washington, D. C. 20375-5341

Abstract

A new chiral synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidiny]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (**2**, J-113397) was developed. J-113397 has a $K_e = 0.85$ nM in an ORL-1 calcium mobilization assay and is 89-, 887-, and 227-fold selective for the ORL-1 receptor relative to the μ , δ , and κ opioid receptors.

Keywords

J-113397; ORL-1 antagonist; chiral synthesis; NOP

1. Introduction

The opioid-like receptor (ORL-1), also known as OP4 and recently named NOP (the fourth member of the opioid peptide receptor family) or nociceptin/orphanin FQ receptor, was identified in 1994 as an orphan opioid receptor.^{1, 2} Even though this G-protein coupled receptor displays a significant homology with the classical μ -, κ -, δ -opioid receptors (NOP, KOP, and DOP, respectively), it does not bind classical opioid ligands with high affinity. A 17 amino acid peptide was identified in 1995 as an endogenous ligand for ORL-1, and was named nociceptin (NC) or orphanin FQ (OFQ) (**1**).³ It was found to be specific to ORL-1,⁴ as it did not bind other opioid receptors. Nociceptin and ORL-1 receptors are widely distributed in the central nervous system and appear to play an important role in anxiety,⁵ pain,⁶ cognition,^{7–10} and locomotion.¹¹ Importantly, antagonists for this system may be useful in pain management without having the undesirable side effects of opioids such as abuse, dependence

*Corresponding author: Dr. F. Ivy Carroll, Research Triangle Institute, Post Office Box 12194, Research Triangle Park, NC 27709-2194, Telephone: 919 541-6679, Fax: 919 541-8868, e-mail: fic@rti.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

and withdrawal.¹² The first selective small organic molecule antagonist, 1-[(3*R*,4*R*)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2*H*-benzimidazol-2-one (J-113397, **2**, Chart 1) was reported by Ozaki et al. in 1998.^{13–15} The lead compound 1-(1-benzyl-4-piperidinyl)-1,3-dihydro-2*H*-benzimidazol-2-one (**3**, Chart 1) was identified from a chemical library and showed high affinity for ORL-1 but poor selectivity relative to μ - and κ -receptors.

In this study, we report a new synthesis of J-113397 and present its potency at the ORL-1, μ , δ , and κ opioid receptors using in vitro efficacy assays.

2. Chemistry

The synthesis used for **1** is shown in Scheme 1. This synthesis provides the desired optical isomer **2** without the use of a chiral column needed in the originally reported syntheses.^{13–17}

Several groups have reported the reduction of piperidine β -ketoester **5** generated from **4** with Baker's yeast to be both diastereoselective and enantioselective.^{17–19} We were pleased to find that only the *cis* diastereomer **6** was isolated in good yield (78%), however, in our hands the enantioselectivity was quite low (ee around 30%) despite numerous changes to conditions. Other groups have reported this problem²⁰ with the activity of the yeast at the heart of the problem. The optical rotation of the product **6** varies from batch to batch of yeast (from +5 to +15°). To overcome this problem, the single diastereomer was reduced with lithium borohydride and protected as the *tert*-butyldimethylsilyl ether **7**. The secondary alcohol was converted to the azide **8** using the Mitsunobu conditions with zinc azide/bis pyridine complex,²¹ resulting in complete inversion of configuration at C-4 of the piperidine ring. The primary amine, ($\pm$)-**9**, obtained by hydrogenation of the azide, was resolved to give (+)- and (–)-**9** using (+)- and (–)-3-bromo-8-camphorsulfonic acid ammonium salt. A single crystal X-ray analysis of the (–)-3-bromo-8-camphorsulfonic acid salt showed that (–)-**9** possessed the (3*S*,4*S*)-stereochemistry and thus (+)-**9** was the (3*R*,4*R*)-isomer (Figure 1). Thus, (+)-**9** was used to complete the synthesis of **2**. From this versatile intermediate, the synthesis of **2** proceeded by coupling the chiral 4-amino-piperidine (+)-**9** with 1-fluoro-2-nitrobenzene to give **10** in high yield (88%). Reduction of the nitro-group using Raney Nickel and hydrazine hydrate in ethanol followed by treatment with *N,N'*-disuccinimidyl carbonate afforded benzimidazolone **11** in 91% yield. Chiral-HPLC analysis of **11** showed a 99% ee. Alkylation of the benzimidazolone nitrogen with sodium hydride and iodoethane in DMF, followed by removal of the *tert*-butoxycarbonyl and *tert*-butyldimethylsilyl protecting groups with hydrogen chloride in methanol afforded the deprotected piperidine intermediate **12**. Reductive alkylation of **12** with cyclooctanecarboxaldehyde using sodium triacetoxyborohydride afforded **2** (J-113397) with an optical rotation almost identical to that previously described {observed $[\alpha]_D^{20} = +6.25$ (*c* 0.272, 0.1 M HCl), lit. $[\alpha]_D^{20} = +6.4$ (*c* 1, 0.1 M HCl)}.

3. Biology

Creation of an ORL-1 stable cell line

Human ORL-1 cDNA in the mammalian expression vector pcDNA3.1+ was purchased from the University of Missouri-Rolla cDNA Resource Center. CHO cells stably expressing the promiscuous G_q protein $G_{\alpha 16}$ (Molecular Devices, Sunnyvale, CA) were transfected with the ORL-1 vector using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). This was done in order to create a cell line where ORL-1 is also coupled to activation of phospholipase C and the mobilization of internal calcium in addition to G_i . The transfected cells were selected in 400 μ g/ml geneticin. The clone used for this experiment was selected after screening the surviving cells for functional ORL-1 receptor expression using nociceptin and the Calcium 3 assay kit

(Molecular Devices). These assays were run according to manufactures specifications using a FlexStationII384 plate reader (Molecular Devices) pre-warmed to 37 °C.

Functional assays and data analysis

Compound **2** was evaluated at 10 μ M for intrinsic activity and for its ability to inhibit the mobilization of internal calcium and subsequent fluorescence elicited by nociceptin (EC_{80} ; 1.5 nM). All test conditions were run in duplicate. For these assays, 96-well cell culture plates were seeded with 10,000 cells the day before the assay. On the day of assay, the cells were incubated at 37 °C with the Calcium 3 fluorescent dye (1/3 the standard concentration) for 1 hr. For the antagonist assays, the test compound was added fifteen minutes before the end of the incubation period. The plate was then placed into the FlexStation (37 °C) and basal fluorescence recorded for 13 sec followed by the addition of test compound or nociceptin (EC_{80}), and fluorescence recorded for an additional 47 sec. The effect of **2** on the mobilization of internal calcium was determined using the MAX-MIN option in the recording software. Because **2** did not possess detectable intrinsic activity and it inhibited nociception-stimulated mobilization of internal calcium, it had its apparent affinity (K_e) determined. For these experiments, we assessed the ability of a single concentration of **2** to shift the nociceptin concentration response curve to the right using the same assay conditions described above. The EC_{50} values for nociceptin (A) and nociceptin + **2** (A') were used to calculate the test compound K_e using the formula: $K_e = [L]/(DR-1)$, where [L] equals the concentration of **2** in the assay and DR equals the dose ratio or A'/A. The concentration of test compound was selected to produce at least a two-fold increase in the nociceptin EC_{50} , and eight different concentrations of nociceptin were used such that clear upper and lower asymptotes were obtained for both curves. Two different concentrations of **2** were used to determine its K_e . Compound **2** was then evaluated for its activity (agonist and antagonist) and selectivity for the human κ , μ , and δ opioid receptors using the [35 S]GTP γ S functional binding assay and membrane homogenates prepared from CHO cells stably expressing one of these receptors. The [35 S]GTP γ S binding assays were conducted as previously described.²² A three-parameter logistic equation (shared bottom and top) was fit to the concentration response data with Prism (v4 for Macintosh, GraphPad Software; San Diego, CA) to calculate the EC_{50} values. These values are reported as the mean $\pm$ SE from at least three independent experiments.

4. Results and Discussion

The original synthesis¹³ of **2** as well as an improved synthesis described by Kawamoto,¹⁷ and De Risi et al.¹⁶ committed to a choice of N-substituent in the first step and involved the use of a chiral column. In a more recent report, Sulima et al reported a new approach for the synthesis of J-113397 that did not require a chiral column.²³ In this study, we developed an alternate synthetic approach to **2** where the N-substituent is added in the last step (Scheme 1). Thus, in contrast to the Kawamoto type synthesis¹⁷ the present route could be used to prepare **2** as well as N-substituent analogs of **2**. The present synthesis involves fourteen steps starting with **4** (one, an optical resolution; another, the neutralization of the resolved salt to give the freebase) with eight isolated intermediates. Note, however, intermediate **5** is commercially available. We chose to synthesize **5** since we had a large amount of **4** on hand. The overall yield was 6%. The Kawamoto synthesis involves nine steps (one being a separation of diastereoisomers and one a resolution with a chiral column) with six isolated intermediates. The overall yield was 8.3%.

In agreement with the originally reported data,¹³ we found that **2** is a potent antagonist at the ORL-1 receptor (K_e = 0.85 nM). We found that **2** was 89-, 887-, and 227-fold selective for the ORL-1 receptor relative to the μ , δ , and κ opioid receptors respectively. While these selectivities are good, they are much less than the 956-, > 4347-, and 609-fold selectivity for

the ORL-1 receptor relative to the μ , δ , and κ opioid receptors originally reported using competition binding assays using opioid receptors heterologously expressed in CHO cells.¹³ These differences in selectivity between the assays could be due to our use of functional assays that assess the ability of **2** to disrupt receptor activation by an agonist as opposed to interfering with the binding of a radioligand. Nevertheless, the rank order potency of **2** at the various receptors is similar in both assays.

In summary, a new synthesis of the ORL-antagonist **2**, which proceeds without the need of a chiral column was developed. Coupling the human ORL-1 to the mobilization of internal calcium via G α 16 identified J-113397 as a potent ORL-1 antagonist, and more importantly, it provides a rapid method to evaluate compounds at this receptor.

5. Experimental

Melting points were determined on a Thomas-Hoover capillary tube apparatus. All optical rotations were determined at the sodium D line using a Rudolph Research Autopol III polarimeter (1 dm cell). NMR spectra were recorded on a 300 MHz (Bruker AVANCE 300) spectrometer using tetramethylsilane as internal standard. Chromatography was performed using a CombiFlash Companion and RediSep columns by Isco, using the solvent system specified in the section below. Elemental analyses were carried out by Atlantic Microlab, Inc. Baker's yeast was purchased from ICN biomedical.

Synthesis of 1-*tert*-butyl-3-ethyl-4-oxopiperidine-1,3-dicarboxylate (**5**)

A solution of di-*tert*-butyl dicarbonate (35.5 g, 0.17 mol) in CH₂Cl₂ (70 mL, anhydrous) was added dropwise to a stirred solution of ethyl 4-oxopiperidine-3-carboxylate hydrochloride (**4**, 30.4 g, 0.146 mol) and triethylamine (29 mL, 208 mmol) in CH₂Cl₂ (70 mL, anhydrous). After being stirred at rt for 16 h, the reaction mixture was washed with HCl (1 M, 2 $\times$ 250 mL) and brine (2 $\times$ 150 mL). The organic layer was dried over Na₂SO₄ and evaporated to dryness under reduced pressure to afford 40 g (100%) of **5** as a white solid. The material was used without further purification. ¹H NMR (CDCl₃) δ 12.06 (s, 1H), 4.25 (q, 2H, *J* = 6.9 Hz), 4.08 (bs, 2H), 3.58 (t, 2H, *J* = 5.85 Hz), 2.39 (t, 2H, *J* = 5.85 Hz), 1.49 (s, 9H), 1.32 (t, 3H, *J* = 6.9 Hz); ¹³C NMR (CDCl₃) δ 170.8, 168.05, 154.6, 96.29, 80.1, 60.6, 40.7, 40.3, 28.7, 28.4, 14.2; MS (APCI) *m/z* 172.1 (M+H-BOC)⁺.

1-*tert*-butyl-3-ethyl (3,4-*cis*)-4-hydroxypiperidine-1,3-dicarboxylate (**6**)

Baker's yeast (210 g, dry active), sucrose (210 g, pure cane sugar) and tap water (2100 mL) were mixed in a vat (~20 L). The mixture was stirred for 6 h at rt, after which no rising in the yeast was observed. To the yeast mixture was added 1-*tert*-butyl-3-ethyl-4-oxopiperidine-1,3-dicarboxylate (**5**) (26.1 g, 0.096 mol) in EtOH (100 mL). After being stirred at rt for 65 h, the reaction mixture was transferred to six 250 mL-centrifuge bottles and centrifuged at 5000 rpm for 20 min at 8 °C. The supernatant in each bottle was decanted and the solids were mixed with water (180 mL per bottle). The mixture was centrifuged again at 5000 rpm for 20 min at 5 °C. The supernatants were pooled and the washing process of the solids was repeated 2 more times. All the supernatants were combined and extracted with CH₂Cl₂ (5 $\times$ 800 mL). The organic phases with a small amount of emulsion were combined and washed with brine (1 L), dried over Na₂SO₄ and filtered through a membrane filter with Celite on top. The solvent was evaporated and the residue was dried *in vacuo* to give 18 g (69%) of **6** as a white solid. $[\alpha]_D^{20} +10.5$ (c 1.34, CH₂Cl₂)

The remaining solids were mixed with MeOH (150 mL per bottle). The mixture was filtered through a Celite pad. The filter cake was washed with MeOH (2 $\times$ 20 mL). All the filtrates were combined, concentrated to about 250 mL, extracted with CHCl₃ (4 $\times$ 50 mL). The extracts

were combined, washed with brine (3 × 50 mL) and dried over Na₂SO₄. Evaporation of the solvent under reduced pressure afforded an additional 2.11 g (8%) of **6** as an orange oil (total yield: 77%). ¹H NMR (CDCl₃) δ 4.29 (bs, 1H), 4.19 (q, 2H, *J* = 7.2 Hz), 4.17 (bs, 1H), 3.73 (dt, 1H, *J* = 3.6 and 13.2 Hz), 3.40 (bs, 1H), 3.34–3.25 (m, 1H), 2.66–2.61 (m, 1H), 1.88–1.83 (m, 1H), 1.69–1.66 (bs, 2H), 1.48 (s, 9H), 1.30 (t, 3H, *J* = 7.2 Hz); ¹³C NMR (CDCl₃) δ 173.4, 155.1, 104.5, 80.2, 65.4, 61.4, 46.3, 41.0, 39.1, 31.8, 29.0, 28.8, 14.5; MS (ESI) *m/z* 274.6 (M+H)⁺.

3-(*tert*-butyldimethylsilanyloxymethyl)-piperidine-1-carboxylic acid *tert*-butyl ester (**7**)

To a solution of 1-*tert*-butyl-3-ethyl (3,4-*cis*)-4-hydroxypiperidine-1,3-dicarboxylate (**6**) (8.78 g, 0.032 mol) in anhydrous THF (1000 mL) was added dropwise a solution of LiBH₄ in THF (16.1 mL, 32.2 mmol). The reaction mixture was then heated at reflux for 10 min and allowed to cool to rt over 20 min. The mixture was cooled to 0 °C and an aqueous saturated solution of KHSO₄ (1000 mL) was slowly added. The two layers were separated and the aqueous phase was extracted with EtOAc (2 × 500 mL). The combined organic layers (including the THF layer from the first separation) were washed with brine (600 mL), dried over MgSO₄ and evaporated to dryness to give 7.43 g (99.5%) of (3,4-*cis*)-4-hydroxy-3-hydroxymethylpiperidine-1-carboxylic acid *tert*-butyl ester as a clear oil. ¹H NMR (CDCl₃) δ 4.23–4.19 (m, 1H), 4.21 (t, 2H, *J* = 3 Hz), 3.56 (dd, 2H, *J* = 3.9 and 13.2 Hz), 3.43–3.36 (m, 2H), 3.29 (bs, 1H), 1.87–1.68 (m, 4H), 1.47 (s, 9H); ¹³C NMR (CDCl₃) δ 211.2, 80.1, 69.9, 63.4, 54.2, 42.0, 32.5, 32.1, 29.6, 28.8, 25.2; MS (APCI) *m/z* 132.2 (M+H-BOC)⁺.

To a solution of (3,4-*cis*)-4-hydroxy-3-hydroxymethylpiperidine-1-carboxylic acid *tert*-butyl ester (7.39 g, 0.032 mol) in anhydrous CH₂Cl₂ (65 mL) were added 4-dimethylaminopyridine (0.43 g, 0.035 mol), triethylamine (5.8 mL, 41.54 mmol) and finally *t*-butyldimethylsilyl chloride (5.8 g, 0.039 mol). The mixture was stirred at rt for 16 h, during that time the reaction turned cloudy with some solid at the bottom and on the walls of the flask. The reaction mixture was diluted with 500 mL of CH₂Cl₂, washed with water (2 × 50 mL) and brine (50 mL). The organic layer was dried over Na₂SO₄, evaporated to dryness and dried under vacuum to give 11 g (99.7 %) of **7** as a clear oil. ¹H NMR (CDCl₃) δ 4.15 (bs, 1H), 3.73 (bs, 1H), 3.51 (dd, 2H, *J* = 3.9 and 13.2 Hz), 3.38–3.29 (m, 3H), 1.82–1.64 (m, 3H), 1.43 (s, 9H), 0.89 (s, 9H), 0.06 (s, 6H); ¹³C NMR (CDCl₃) δ 148.9, 107.0, 80.2, 68.4, 42.0, 39.4, 32.4, 28.8, 26.1, 18.4, –3.2; MS (APCI) *m/z* 246.5 (M+H-BOC)⁺.

4-azido-3-(*tert*-butyldimethylsilanyloxymethyl)-piperidine-1-carboxylic acid *tert*-butyl ester (**8**)

To a solution of 3-(*tert*-butyldimethylsilanyloxymethyl)-piperidine-1-carboxylic acid *tert*-butyl ester (**7**) (1.23 g, 0.0036 mol) and triphenylphosphine (1.88 g, 0.007 mol) in anhydrous toluene (18 mL) was added zinc azide bis pyridine complex (830 mg, 2.68 mmol). The mixture was stirred at rt for 5 min then cooled to 0 °C. Diisopropylazodicarboxylate (1.38 mL, 7.14 mmol) was then slowly added to the mixture. The ice bath was removed and the reaction mixture was stirred at rt for 4 h. The reaction mixture was then filtered through a pad of Celite (3 cm). The filter cake was washed with 20% EtOAc-hexanes (2 × 25 mL). All the filtrates were combined and concentrated to 3.4 g. The crude product was then purified by using a RediSep column (SiO₂, 40 g) eluted with 0–10% B (0–5 min) (A = hexanes, B = EtOAc), 10% B (5–13 min), 10–20% B (13–17 min), 20% B (17–20 min) and 20–40% B (20–25 min), to give 0.882 g (68%) of **8** as a clear oil. ¹H NMR (CDCl₃) δ 4.07 (dd, 2H, *J* = 3.2 and 13.1 Hz), 3.67 (bs, 2H), 3.37 (bs, 2H), 2.81–2.73 (m, 2H), 2.03–1.98 (m, 1H), 1.60–1.55 (m, 3H), 1.46 (s, 9H), 0.90 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H); ¹³C NMR (CDCl₃) δ 155.1, 132.6, 132.5, 129.0, 128.8, 80.2, 62.1, 59.6, 43.7, 42.5, 30.5, 28.9, 28.8, 26.4, 26.3, 22.1, –5.2.

4-amino-3-(*tert*-butyldimethylsilanyloxymethyl)-piperidine-1-carboxylic acid *tert* butyl ester (9)

Anhydrous methanol (100 mL) was added to a mixture of 4-azido-3-(*tert*-butyldimethylsilanyloxymethyl)-piperidine-1-carboxylic acid *tert*-butyl ester (**8**) (5.74 g, 0.015 mol) and palladium on active carbon (10% wt, 0.6 g). The reaction flask was connected to a hydrogenation system and the mixture was degassed then stirred under H₂ for 16 h. The reaction mixture was then filtered through a pad of Celite and the filter cake was washed with methanol (2 × 50 mL). The filtrates were combined then evaporated to dryness to give 5.24 g of product. Purification of the product by flash chromatography (SiO₂, 40% EtOAc/hexanes) CHCl₃-CH₃OH-NH₄OH (80:18:2) then afforded 3.56 g (67%) of **9** as a clear oil. ¹H NMR (CDCl₃) δ 4.07–4.01 (m, 2H), 3.66 (bs, 2H), 2.66 (t, 2H, *J* = 12 Hz), 2.52–2.44 (m, 1H), 1.76–1.70 (m, 1H), 1.40 (s, 9H), 1.35–1.22 (m, 4H), 0.84 (s, 9H), 0.06 (s, 6H); ¹³C NMR (CDCl₃) δ 155.2, 79.9, 63.4, 50.8, 46.8, 43.0, 35.6, 28.8, 28.5, 26.3, 18.6, –5.1; MS (APCI) *m/z* 345.5 (M+H)⁺.

Resolution of racemic amine 9 using (+)-3-bromo-8-camphorsulfonic acid ammonium salt

4-Amino-3-(*tert*-butyldimethylsilanyloxymethyl)-piperidine-1-carboxylic acid *tert*-butyl ester (**9**) (805 mg, 2.34 mmol) was dissolved in methanol (8 mL). To the well-stirred solution was added [(1R)-(endo, anti)]-(+)-3-bromocamphor-8-sulfonic acid, ammonium salt (390 mg, 1.17 mmol). The mixture was stirred until a clear mixture was observed (about 20 min). The solvent was slowly evaporated under a stream of N₂ (3.5 h). An additional volume of methanol (2 mL) was added and evaporated under N₂ to give a thick oil that was placed under vacuum yielding a white foam. That foam was dissolved in *tert*-butyl methyl ether (TBME) (2 mL). The solvent was slowly evaporated under a stream of N₂ (0.5 h). Toluene (6 mL) was added, followed by hexanes (2 mL) and the solution was left at rt for 16 h. The resulting crystals were washed with 50% toluene-hexanes (5 mL), then with hexanes (5 mL). The white crystals were dried under vacuum to give 357 mg of resolved complex. Part of the crystals (22 mg) was dissolved in CHCl₃ (1 mL), and NaHCO₃ (saturated, 1 mL) was added. The mixture was stirred at rt for 30 min. The phases were separated and the aqueous layer was extracted with CHCl₃ (2 × 1 mL). The combined organic layers were washed with brine (1 mL), dried over Na₂SO₄ and evaporated to dryness to give 14 mg of free amine. [α]_D²⁰ +11.53 (c 0.23, CH₃OH).

The mother liquor was dissolved in CHCl₃ (10 mL), and treated with NaHCO₃ (saturated, 10 mL). The mixture was stirred at rt for 30 min. The phases were separated and the aqueous layer was extracted with CHCl₃ (2 × 10 mL). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄ and evaporated to dryness to give 560 mg of free amine. [α]_D²⁰ –5.5, (c 1.09, CH₃OH).

The rest of the resolved complex was dissolved in CHCl₃ (20 mL), and treated with NaHCO₃ (saturated, 20 mL). The mixture was stirred at rt for 30 min. The phases were separated and the aqueous layer was extracted with CHCl₃ (2 × 10 mL). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄ and evaporated to dryness to give 0.177 g of resolved free amine.

Resolution of 9 using (–)-3-bromo-8-camphorsulphonic acid ammonium salt

From 343 mg of **9** (1 mmol) and [(1S)-endo, anti]-(–)-3-bromocamphor-8-sulphonic acid ammonium salt (333 mg, 1.0 mmol) in methanol as described above the respective (–)-sulphonic acid salt was prepared. The resulting glassy solid was dissolved in 2 mL of TBME at ambient temperature and allowed to crystallize undisturbed for 15 h. The solution was very slowly concentrated to half the volume over a 4 h period. The crystalline salt was carefully separated by filtration, washed with three 0.4 mL portions of TBME. The combined filtrate

and washings were allowed to slowly evaporate to half the volume, which furnished additional crystalline salt. After filtration this salt was washed with toluene-30% TBME and combined with the first fraction to yield 217 mg of white crystalline salt. This material was dissolved in 1.5 mL of ethyl acetate, 3 volumes of toluene were added and the solution was concentrated to an oil. A solution of the material in 2 mL of toluene was left to crystallize undisturbed for 30 h. White clusters of crystals were separated and washed twice with 0.5 mL toluene and air dried for 2 h. An ^1H -NMR spectrum (CDCl_3) showed characteristic signals at δ 7.89 (bs, 3H), 4.46 (d, 1H, $J = 3\text{ Hz}$), 1.32 (s, 9H), 1.08 (s, 3H), 0.83 (s, 3H), 0.79 (s, 9H), 0.14 (s, 6H). A sample of 20 mg was used for X-ray diffraction analysis.

3-(*tert*-butyldimethylsilanyloxymethyl)-4-(2-nitrophenylamino)-piperidine-1-carboxylic acid *tert*-butyl ester (10)

A mixture of resolved amine (+)-**9** (172 mg, 0.5 mmol), sodium carbonate (64 mg, 0.6 mmol), *n*-butanol (5 mL) and 1-fluoro-2-nitrobenzene (0.16 mL, 0.75 mmol) was refluxed for 4 h. The reaction mixture was cooled to rt, filtered through a pad of Celite. The flask was washed with ether (3 $\times$ 10 mL) and the washing was filtered through the pad. The filtrates were combined, washed with water (2 $\times$ 5 mL) and brine (5 mL) and dried over Na_2SO_4 . The solvent was evaporated under reduced pressure and the residue was purified by column chromatography (SiO_2 , 10% EtOAc/hexanes) to afford 192 mg (88%) of pure product **10**. ^1H NMR (CDCl_3) δ 8.18 (d, 1H, $J = 8.67\text{ Hz}$), 8.09 (d, 1H, $J = 8.29\text{ Hz}$), 7.40 (t, 1H, $J = 7.54\text{ Hz}$), 7.02 (bs, 1H), 6.64 (t, 1H, $J = 7.8\text{ Hz}$), 4.28–3.95 (m, 2H), 3.71–3.65 (m, 3H), 3.20–2.76 (m, 2H), 2.09 (bd, 1H, $J = 12\text{ Hz}$), 1.75–1.74 (m, 1H), 1.49 (s, 9H), 0.87 (s, 9H), 0.01 (s, 3H), -0.07 (s, 3H); ^{13}C NMR (CDCl_3) δ 162.5, 154.9, 145.3, 136.4, 127.3, 115.6, 114.4, 80.1, 61.7, 50.1, 44.3, 28.6, 28.0, 18.7, -5.5 ; MS (APCI) m/z 366.9 ($\text{M}+\text{H}-\text{BOC}$) $^+$.

3-(*tert*-butyldimethylsilanyloxymethyl)-4-(2-oxo-2,3-dihydro-benzimidazol-1-yl)-piperidine-1-carboxylic acid *tert*-butyl ester (11)

To a solution of pure nitro compound **10** (587 mg, 1.26 mmol) in EtOH (20 mL) were added Raney Nickel (2.2 mL) and hydrazine hydrate (0.74 mL, 15 mmol). The mixture was stirred at rt for 2 h and then filtered through a pad of Celite. The flask was washed with EtOH (50 mL) and the washings were filtered through the pad. The filtrates were combined and concentrated. The residue was dissolved in Et_2O (10 mL), washed with brine (10 mL) and dried over Na_2SO_4 . The solvent was evaporated under reduced pressure and the residue was dried *in vacuo* to give 510 mg (91%) of 3-(*tert*-butyl-dimethylsilanyloxymethyl)-4-(2-aminophenylamino)-piperidine-1-carboxylic acid *tert*-butyl ester as orange foam. ^1H NMR (CDCl_3) δ 6.77–6.68 (m, 4H), 4.14 (dd, 1H, $J = 4$ and 13.5 Hz), 3.75–3.72 (m, 2H), 3.38 (bs, 5H), 2.92–2.79 (m, 2H), 2.11 (dd, 1H, $J = 3.15$ and 13 Hz), 1.68–1.65 (m, 1H), 1.47 (s, 9H), 0.90 (s, 9H), 0.04 (s, 3H), 0.02 (s, 3H); ^{13}C NMR (CDCl_3) δ 155.0, 136.4, 126.0, 120.6, 119.3, 117.1, 79.7, 62.9, 51.5, 28.6, 26.1, 18.4, -5.3 ; MS (APCI) m/z 436.7 ($\text{M}+\text{H}$) $^+$.

3-(*tert*-Butyldimethylsilanyloxymethyl)-4-(2-amino-phenylamino)-piperidine-1-carboxylic acid *tert*-butyl ester (510 mg, 1.17 mmol) and $\text{N,N}'$ -disuccinimidyl carbonate (600 mg, 2.34 mmol) were dissolved in DMF (20 mL). The reaction mixture was stirred at rt for 2 days. It was then treated with brine (5 mL) and water (5 mL). The aqueous phase was extracted with Et_2O (4 $\times$ 10 mL). The combined organic phase was washed with brine (2 $\times$ 5 mL) and dried over Na_2SO_4 . Evaporation of the solvent under reduced pressure afforded 600 mg (100%) of **11** as an orange oil. The chiral purity of benzimidazolone **11** was determined by chiral-HPLC: ChromTech Chiral-AGP column 4 $\times$ 150 mm, 5 μm , solvent A: [10 mM K_2HPO_4 + KH_2PO_4 , pH = 7.0], solvent B: CH_3OH , 5% B, flow rate: 1 mL/min, UV: 235 nm, retention time: 16.8 min. ^1H NMR (CDCl_3) δ 10.74 (s, 1H), 7.11–7.00 (m, 4H), 4.36–4.32 (m, 2H), 3.44–3.37 (m, 2H), 2.80–2.38 (m, 5H), 1.80–1.77 (m, 1H), 1.48 (s, 9H), 0.78 (s, 9H), -0.17

(s, 3H), -0.19 (s, 3H); ^{13}C NMR (CDCl_3) δ 155.6, 154.9, 128.4, 121.4, 121.0, 109.9, 79.9, 61.8, 51.9, 36.6, 28.6, 25.9, 18.2, -5.6; MS (ESI) m/z 460.9 ($\text{M}-\text{H}$) $^-$.

1-ethyl-3-(3-hydroxymethyl-4-piperidiny)-1,3-dihydrobenzimidazol-2-one (12)

To a solution of benzimidazolone **11** (600 mg, 1.17 mmol) in DMF (25 mL) cooled at 0 °C was added NaH (60% suspension in mineral oil, 170 mg, 4.2 mmol). The reaction mixture was slowly warmed to rt over 1 h. Iodoethane (0.59 mL, 7.3 mmol) was added and the reaction mixture was stirred at rt for 90 min. It was then cooled to 0 °C and treated with water (30 mL). The aqueous phase was extracted with EtOAc (4 $\times$ 15 mL). The combined organic layer was washed with brine (15 mL) and dried over Na_2SO_4 . Evaporation of the solvent under reduced pressure afforded 580 mg (100%) of 3-(*tert*-butyldimethylsilanyloxymethyl)-4-(3-ethyl-2-oxo-2,3-dihydrobenzimidazol-1-yl)-piperidine-1-carboxylic acid *tert*-butyl ester. ^1H NMR (CDCl_3) δ 7.13–6.99 (m, 4H), 4.39–4.27 (m, 3H), 3.93 (q, 2H, J = 7.3 Hz), 3.43–3.33 (m, 2H), 2.96–2.37 (m, 4H), 1.79 (d, 2H, J = 11.1 Hz), 1.50 (s, 9H), 1.33 (t, 3H, J = 7.1 Hz), 0.81 (s, 9H), -0.13 (s, 3H), -0.15 (s, 3H); ^{13}C NMR (CDCl_3) δ 154.8, 153.5, 129.2, 121.0, 120.9, 109.1, 107.6, 79.8, 62.0, 52.3, 35.8, 29.8, 29.4, 28.9, 28.5, 25.9, 18.2, 13.6, -5.7; MS (ESI) m/z 490.8 ($\text{M}+\text{H}$) $^+$.

3-(*tert*-butyldimethylsilanyloxymethyl)-4-(3-ethyl-2-oxo-2,3-dihydrobenzimidazol-1-yl)-piperidine-1-carboxylic acid *tert*-butyl ester (130 mg, 0.27 mmol) was dissolved in HCl/MeOH (10% vv, 4.5 mL). The solution was stirred at rt for 3 h, then concentrated to about 1 mL. The residue was mixed with aqueous HCl (0.5 M, 5 mL). The aqueous solution was washed with Et_2O (3 $\times$ 3 mL), basified to pH=12 with NaOH (2 M), extracted with CHCl_3 (4 $\times$ 7 mL). The extracts were combined, washed with H_2O (2 $\times$ 5 mL), dried over Na_2SO_4 , dried *in vacuo* to give 56 mg (76%) of **12** as a clear oil. ^1H NMR (CDCl_3) δ 7.32 (d, 1H, J = 7.5 Hz), 7.14–6.89 (m, 3H), 4.47 (dt, 1H, J = 3.7 and 12.2 Hz), 4.02–3.89 (m, 2H), 3.34–3.21 (m, 4H), 2.90–2.45 (m, 5H), 2.26 (bs, 1H), 1.92–1.91 (m, 1H), 1.34 (t, 3H, J = 7.35 Hz); ^{13}C NMR (CDCl_3) δ 154.6, 129.4, 128.3, 121.4, 121.3, 110.2, 108.1, 61.7, 51.9, 49.2, 46.6, 36.2, 30.1, 29.9, 13.7; MS (APCI) m/z 276.3 ($\text{M}+\text{H}$) $^+$.

1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidiny]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (2) Hydrochloride

To a stirred solution of 1-ethyl-3-(3-hydroxymethyl-4-piperidiny)-1,3-dihydrobenzimidazol-2-one (**12**) (24.1 mg, 0.085 mmol) in THF (1 mL) were added cyclooctanecarboxaldehyde (0.01 mL, 0.1 mmol) and sodium triacetoxyborohydride (28 mg, 0.13 mmol). After 2.5 d at rt, the mixture was mixed with EtOAc (1 mL) and H_2O (1 mL). The organic layer was separated, washed with NaHCO_3 (satd, 1 mL), brine (1 mL), dried over Na_2SO_4 , and placed under vacuum. Purification of the crude product by prep TLC (Silica gel, 1000 μm) with 70% EtOAc/hexanes afforded 14.4 mg (42%) of **2**. ^1H NMR (CDCl_3) δ 7.33–7.27 (m, 1H), 7.20–7.02 (m, 3H), 4.37 (dq, 1H, J = 3.8 Hz), 3.98–3.92 (m, 2H), 3.33 (bs, 2H), 3.00 (d, 3H, J = 9.42 Hz), 2.60 (dq, 1H, J = 3.7 and 12.3 Hz), 2.31–2.03 (m, 5H), 1.72–1.46 (m, 14H), 1.34 (t, 3H, J = 7.1 Hz), 1.28–1.22 (m, 2H); ^{13}C NMR (CDCl_3) δ 155.0, 129.7, 128.5, 122.2, 121.5, 121.5, 110.6, 108.3, 66.5, 62.3, 56.9, 54.0, 52.2, 41.4, 36.5, 35.3, 31.3, 31.3, 29.8, 29.2, 27.6, 27.6, 26.8, 26.0, 26.0, 25.4, 13.9; MS (ESI) m/z 400.6 ($\text{M}+\text{H}$) $^+$.

1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidiny]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (14.4 mg) was dissolved in 10% MeOH/HCl (1 mL). The solvent was removed under reduced pressure and the oily residue was then dissolved in Et_2O (1 mL). Some white solids precipitated on the flask walls. The solvent was removed under reduced pressure and the residue was placed under vacuum to give 13.6 mg of the hydrochloride salt as a white solid. $[\alpha]_D^{20}$ = +6.25 (*c* 0.272, 0.1 M HCl). ($\text{C}_{24}\text{H}_{38}\text{ClN}_3\text{O}_2 \cdot \text{H}_2\text{O}$) C, H, N.

X-ray Crystal Structure of (–)-3-Bromo-8-Camphorsulphonic Acid Salt of (–)-9

Single-crystal x-ray diffraction data were collected at 295°K using CuK α radiation and a Bruker SMART 6000 CCD area detector. A $0.42 \times 0.10 \times 0.07$ mm³ crystal was mounted on a glass rod and transferred to the diffractometer. The crystal was orthorhombic in space group $P2_12_12_1$ with unit cell dimensions $a = 6.9722(2)$ Å, $b = 20.3743(6)$ Å, $c = 24.2633(7)$ Å. Corrections were applied for Lorentz, polarization, and absorption effects. Data were 98.1% complete to $67.16^\circ \theta$ (approximately 0.83 Å) with an average redundancy of 5.0. The structure was solved by direct methods and refined by full-matrix least squares on F_2 values using the programs found in the SHELXTL suite (Bruker, SHELXTL v6.12, 2006, Bruker AXS Inc., Madison, WI). Parameters refined included atomic coordinates and anisotropic thermal parameters for all non-hydrogen atoms. Hydrogen atoms on carbons were included using a riding model [coordinate shifts of C applied to H atoms] with C-H distance set at 0.96 Å. The absolute configuration was set based on the reference molecule (3-bromocamphorsulfonic acid) of known configuration. The t-butyl group off N1 was refined with a disorder over two positions with an occupancy ratio of 52:48. The t-butyl group off the silica atom showed a similar disorder, but the occupancy of the minor position was less than 25% and this disorder was omitted from the final cycles of refinement.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment

This research was supported by the National Institute on Drug Abuse, Grants DA05477 and DA09045.

References

1. Barlocco D, Cignarella G, Giardina GA, Toma L. The opioid-receptor-like 1 (ORL-1) as a potential target for new analgesics. *Eur. J. Med. Chem* 2000;35(3):275–282. [PubMed: 10785553]
2. Mollereau C, Parmentier ML, Mailleux P, Butour J-L, Moisand C, Chalon P, Caput D, Vassart G, Meunier J-C. ORL1, a novel member of the opioid receptor family: Cloning functional expression and localization. *FEBS Lett* 1994;341:33–38. [PubMed: 8137918]
3. Chiou LC, Liao YY, Fan PC, Kuo PH, Wang CH, Riemer C, Prinssen EP. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications. *Curr. Drug Targets* 2007;8(1):117–135. [PubMed: 17266536]
4. Meunier J-C, et al. Isolation and structure of the endogenous agonist of the opioid receptor-like ORL₁ receptor. *Nature* 1995;377:532–535. [PubMed: 7566152]
5. Jenck F, Moreau JL, Martin JR, et al. Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. *Proc. Natl. Acad. Sci* 1997;94:14854–14858. [PubMed: 9405703]
6. Mogil JS, Grisel JE, Reinscheid RK, Civelli O, Belknap JK, Grandy DK. Orphanin FQ is a functional anti-opioid peptide. *Neuroscience* 1996;75(2):333–337. [PubMed: 8930999]
7. Manabe T, Noda Y, Mamiya T, Katagiri H, Houtani T, Nishi M, Noda T, Takahashi T, Sugimoto T, Nabeshima T, Takeshima H. Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors. *Nature* 1998;394(6693):577–581. [PubMed: 9707118]
8. Sandin J, Georgieva J, Schott PA, Ogren SO, Terenius L. Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats. *Eur. J. Neurosci* 1997;9(1):194–197. [PubMed: 9042583]
9. Sandin J, Ogren SO, Terenius L. Nociceptin/orphanin FQ modulates spatial learning via ORL-1 receptors in the dorsal hippocampus of the rat. *Brain Res* 2004;997(2):222–233. [PubMed: 14706874]
10. Yu TP, Fein J, Phan T, Evans CJ, Xie CW. Orphanin FQ inhibits synaptic transmission and long-term potentiation in rat hippocampus. *Hippocampus* 1997;7(1):88–94. [PubMed: 9138672]
11. Florin S, Suaudeau C, Meunier JC, Costentin J. Nociceptin stimulates locomotion and exploratory behaviour in mice. *Eur. J. Pharmacol* 1996;317(1):9–13. [PubMed: 8982713]

12. McCleane GJ, Obara I, Mika J, Przewlocka B. Effects of ORL1 Receptor Agonists and Antagonists in Nociception: A Review. *Journal of Neuropathic Pain & Symptom Palliation* 2006;2(1):29–44.
13. Kawamoto H, Ozaki S, Itoh Y, Miyaji M, Arai S, Nakashima H, Kato T, Ohta H, Iwasawa Y. Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397). *J. Med. Chem* 1999;42(25):5061–5063. [PubMed: 10602690]
14. Ozaki, S.; Kawamoto, H.; Ito, Y.; Hirano, K.; Hayashi, K.; Iwasawa, Y. 2-Oxoimidazole Derivatives. Int.. Patent WO 98/54168 (PCT/JP98/02335). 1998.
15. Ozaki S, Kawamoto H, Itoh Y, Miyaji M, Iwasawa Y, Ohta H. A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORL1) antagonist: J-113397. *Eur. J. Pharmacol* 2000;387(3):R17–R18. [PubMed: 10650183]
16. De Risi C, Piero Pollini G, Trapella C, Peretto I, Ronzoni S, Giardina GA. A new synthetic approach to 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-benzimidazol-2-one(J-113397), the first non-peptide ORL-1 receptor antagonist. *Bioorg. Med. Chem* 2001;9(7):1871–1877. [PubMed: 11425589]
17. Kawamoto H, Nakashima H, Kato T, Arai S, Kamata K, Iwasawa Y. Synthesis of J-113397, the first potent and selective ORL1 antagonist. *Tetrahedron* 2001;57(6):981–986.
18. Deol BS, Ridley DD, Simpson GW. Asymmetric reduction of carbonyl compounds by Yeast. II. Preparation of optically active α - and β -hydroxycarboxylic acid derivatives. *Aust. J. Chem* 1976;29:2459–2467.
19. Knight DW, Lewis N, Share AC, Haigh D, Knight DW, Lewis N, Share AC, Haigh D. New members of the chiral pool: β -Hydroxypiperidine carboxylates from Baker's yeast reductions of the corresponding keto-esters. *Tetrahedron Assym* 1993;4:625–628.
20. Byrgesen E, Nielsen J, Willert M, Bols M. Combinatorial chemistry of piperidine based carbohydrate mimics. *Tetrahedron Lett* 1997;38:5697–5700.
21. Viaud MC, Rollin P. Zinc Azide Mediated Mitsunobu Substitution. An Expedient Method for the One-Pot Azidation of Alcohols. *Synthesis* 1990:130–131.
22. Carroll FI, Melvin MS, Nuckols MC, Mascarella SW, Navarro HA, Thomas JB. N-substituted 4 β -methyl-5-(3-hydroxyphenyl)-7 α -amidomorphans are potent, selective kappa opioid receptor antagonists. *J Med Chem* 2006;49(5):1781–1791. [PubMed: 16509593]
23. Sulima A, Folk J, Jacobson AE, Rice KC. A new approach to the synthesis of the nonpeptide NOP receptor Antagonist J-113397. *Synthesis* 2007;10:1547–1553.

Figure 1.

The conformation of (–)-**9** as determined by single-crystal x-ray diffraction. The 3S4S conformation was determined with respect to a reference molecule (3-bromocamphorsulfonic acid) which is not shown in the figure. All hydrogen atoms (except those on C3 and C4) and one of the positions for the disordered t-butyl group off N1 have been omitted for clarity. Displacement ellipsoids are shown at the 30% level.

H-Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-
Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gin-OH

1 (N/OFQ)

2

3

Chart 1.

Scheme 1a.

^aReagents: a) (BOC)₂O, Et₃N, CH₂Cl₂; b) Baker's yeast, sucrose, tap water; c) LiBH₄, THF; d) TBDMSCl, DMAP Et₃N, CH₂Cl₂; e) ZnN₆*2 Py, PPh₃, DIAD, toluene; f) H₂, Pd/C, MeOH; g) (R)-3-bromo-8-camphorsulfonic acid, ammonium salt; h) NaHCO₃, CHCl₃; i) 3-fluoronitrobenzene, *n*-BuOH, Na₂CO₃; j) Raney Ni, hydrazine hydrate, EtOH; k) N,N'-disuccimidyl carbonate, DMF; l) NaH, EtI, DMF; m) HCl, MeOH; n) NaBH(OAc)₃, THF, cyclooctanecarboxaldehyde.

Table 1
Apparent Affinities (K_e) for J-113397 (**2**) at Cloned Human ORL-1, μ , δ , and κ Receptors^a

Compd	K_e (nM)				
	ORL-1	μ	δ	κ	μ /ORL-1
2	0.85 $\pm$.09	75.6 $\pm$ 15	754 $\pm$ 193	195 $\pm$ 34	89
					δ /ORL-1
					887
					κ /ORL-1
					227

^aThe apparent affinities (K_e) for **2** represent the mean $\pm$ SE from at least three independent experiments.